4DMedical: Expanding Respiratory Imaging Leadership Through Philips Partnership
4DMedical Limited (ASX: 4DX) is accelerating its global commercial trajectory following a major expansion of its partnership with Philips, as detailed in the company’s ASX announcement. Under the agreement, Philips will distribute 4DMedical’s CT:VQ™ technology across the United States and Canada, supported by a minimum order commitment of US$10 million over 2026–27. This strategic move enables broad penetration of the North American market through Philips’ extensive healthcare network and dedicated specialist teams. CT:VQ™, an FDA-cleared imaging innovation, provides high-resolution ventilation–perfusion insights using standard non-contrast CT scans, eliminating the need for radiotracers and specialised nuclear medicine infrastructure. With more than one million nuclear VQ scans performed annually in the U.S., 4DMedical is positioned to capture significant market share and potentially replace traditional VQ imaging entirely. This partnership marks a pivotal commercial inflection point, enhancing accessibility to advanced respiratory diagnostics.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
4DMedical: Expanding Respiratory Imaging Leadership Through Philips Partnership
4DMedical Limited (ASX: 4DX) is accelerating its global commercial trajectory following a major expansion of its partnership with Philips, as detailed in the company’s ASX announcement. Under the agreement, Philips will distribute 4DMedical’s CT:VQ™ technology across the United States and Canada, supported by a minimum order commitment of US$10 million over 2026–27. This strategic move enables broad penetration of the North American market through Philips’ extensive healthcare network and dedicated specialist teams. CT:VQ™, an FDA-cleared imaging innovation, provides high-resolution ventilation–perfusion insights using standard non-contrast CT scans, eliminating the need for radiotracers and specialised nuclear medicine infrastructure. With more than one million nuclear VQ scans performed annually in the U.S., 4DMedical is positioned to capture significant market share and potentially replace traditional VQ imaging entirely. This partnership marks a pivotal commercial inflection point, enhancing accessibility to advanced respiratory diagnostics.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au